Gainers
- Merrimack Pharmaceuticals (NASDAQ:MACK) shares rose 180.0% to $11.2 during Wednesday's pre-market session. The company's market cap stands at $150.1 million. As per the news, the Q3 earnings report came out 4 days ago.
- Kala Pharmaceuticals (NASDAQ:KALA) stock rose 22.22% to $6.38. The market value of their outstanding shares is at $9.3 million. As per the news, the Q3 earnings report came out yesterday.
- NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock increased by 21.6% to $1.52. The market value of their outstanding shares is at $1.3 million.
- 180 Life Sciences (NASDAQ:ATNF) stock increased by 10.6% to $0.41. The market value of their outstanding shares is at $15.4 million.
- NeuBase Therapeutics (NASDAQ:NBSE) shares moved upwards by 10.54% to $0.28. The market value of their outstanding shares is at $9.0 million.
- Minerva Neurosciences (NASDAQ:NERV) shares increased by 10.18% to $3.3. The market value of their outstanding shares is at $17.6 million. As per the news, the Q3 earnings report came out today.
Losers
- Lannett (NYSE:LCI) shares decreased by 17.4% to $0.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $17.6 million.
- Orgenesis (NASDAQ:ORGS) shares decreased by 14.19% to $1.21. The company's market cap stands at $30.9 million.
- GoodRx Holdings (NASDAQ:GDRX) stock decreased by 12.79% to $4.57. The company's market cap stands at $1.8 billion. The company's, Q3 earnings came out yesterday.
- Athersys (NASDAQ:ATHX) shares decreased by 10.16% to $1.15. The market value of their outstanding shares is at $14.0 million.
- Baudax Bio (NASDAQ:BXRX) stock fell 9.76% to $0.16. The market value of their outstanding shares is at $3.2 million. As per the press release, Q3 earnings came out yesterday.
- Evotec (NASDAQ:EVO) shares declined by 8.5% to $8.72. The market value of their outstanding shares is at $3.0 billion. As per the press release, Q3 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
